SALIX PHARMACEUTICALS INC - NOTE 1.500% 3/1

Q2 2014 13F Holders as of 30 Jun 2014

Type / Class
Debt / NOTE 1.500% 3/1
Market price (% of par)
196.32%
Total 13F principal
$523,444,220
Principal change
+$13,408,298
Total reported market value
$1,028,074,923
Number of holders
60
Value change
+$29,356,171
Number of buys
22
Number of sells
24

Institutional Holders of SALIX PHARMACEUTICALS INC - NOTE 1.500% 3/1 as of Q2 2014

As of 30 Jun 2014, SALIX PHARMACEUTICALS INC - NOTE 1.500% 3/1 was held by 60 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $523,444,220 in principal (par value) of the bond. The largest 10 bondholders included Citadel Advisors LLC, Calamos Advisors LLC, Invesco Ltd., MACKAY SHIELDS LLC, BANK OF AMERICA CORP /DE/, SYMPHONY ASSET MANAGEMENT LLC, SILVERBACK ASSET MANAGEMENT LLC, BAKER BROS. ADVISORS LP, CAMDEN ASSET MANAGEMENT L P /CA, and LORD, ABBETT & CO. LLC. This page lists 60 institutional bondholders reporting positions for the Q2 2014 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.